Revance Top Management

RVNCDelisted Stock  USD 3.65  0.00  0.00%   
Revance employs about 597 people. The company is managed by 15 executives with a total tenure of roughly 27 years, averaging almost 1.0 years of service per executive, having 39.8 employees per reported executive. Evaluation of Revance's management performance can provide insight into the firm performance.
Mark Foley  CEO
CEO Director
Dustin Sjuts  President
Vice President of Strategy and Sales
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Revance's latest congressional trading

Congressional trading in companies like Revance, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Revance by those in governmental positions are based on the same information available to the general public.
2023-11-02Senator Thomas R CarperAcquired Under $15KVerify
2023-11-01Senator Thomas R CarperAcquired Under $15KVerify

Revance Management Team Effectiveness

The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance's management efficiency ratios could be used to measure how well Revance manages its routine affairs as well as how well it operates its assets and liabilities.

Revance Workforce Comparison

Revance is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,038. Revance retains roughly 597 in number of employees claiming about 12% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.72) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.54) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.54.

Revance Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Revance insiders, such as employees or executives, is commonly permitted as long as it does not rely on Revance's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Revance insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Revance Notable Stakeholders

A Revance stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Revance often face trade-offs trying to please all of them. Revance's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Revance's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark FoleyCEO DirectorProfile
Dustin SjutsVice President of Strategy and SalesProfile
Taryn ConwayVice President of MarketingProfile
Tobin SchilkeCFO and Principal Financial OfficerProfile
Jeanie HerbertSr. Director of Investor RelationsProfile
Dwight JDChief CounselProfile
Conor GallagherHead AestheticsProfile
Erica JordanChief OfficerProfile
Azita NejadVP OperationsProfile
Dwight MoxieChief CounselProfile
Justin FordVP PeopleProfile
Amie KrauseChief OfficerProfile
MD MBAChief OfficerProfile
Jessica SerraHead ESGProfile
Aubrey RankinConsultantProfile

About Revance Management Performance

The success or failure of an entity such as Revance often depends on how effective the management is. Revance management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Revance management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Revance management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. Revance Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 495 people.
Please note, the presentation of Revance's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Revance's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Revance's management manipulating its earnings.

Revance Workforce Analysis

Traditionally, organizations such as Revance use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Revance within its industry.

Revance Manpower Efficiency

Return on Revance Manpower

Revenue Per Employee392K
Revenue Per Executive15.6M
Net Loss Per Employee542.7K
Net Loss Per Executive21.6M
Working Capital Per Employee418.2K
Working Capital Per Executive16.6M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Revance Stock

If you are still planning to invest in Revance check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance's history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Transaction History
View history of all your transactions and understand their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories